The Burden of Hospitalisations for Herpes Zoster Ophtalmicus in Spain (1997-2008)


Purpose: This epidemiological retrospective survey aims to provide population-based estimates of the burden of hospitalisation for herpes zoster ophthalmicus in Spain during a twelve-year period (1997-2008). Methods: All hospital discharges and deaths related to herpes zoster ophthalmicus in patients older than 30 years old from 1997 to 2008 in Spain were obtained. Differences in proportions were assessed by the Chi-square test. ANOVA was used for multiple comparisons. Poisson regression was used to assess differences in the rates. Results: A total of 3029 hospital discharges in patients older than 30 years old were coded as herpes zoster ophthalmicus. Of those, 1009 were coded as primary cause of hospitalization. This corresponds to a hospitalization rate of 0.94 and 0.31 hospitalizations per 100,000 for any position and first diagnostic position, respectively. The 75% of the total discharges were in immunocompetent patients. The herpes zoster ophthalmicus hospitalization rate increased significantly during the study period. This increase was also observed for immunocompetent patients. A total of 127 and 21 deaths occurred in patients ≥ 30 year-old hospitalized with herpes zoster ophthalmicus in any diagnostic position and principal diagnostic code, respectively during the 12-year study period. Of them, 70 (53.4%) were in immunocompetent patients, and, of those 11 were in patients with HZO in the first diagnosis position. The hospitalization rate and case-fatality rate increase significantly with age from 50 years old onwards. Conclusion: HZO, a vaccine preventable disease, still causes hospitalization and death in adults in Spain.

Share and Cite:

R. Gil-Prieto, A. Álvaro-Meca, A. Mena, J. Ortega and Á. Miguel, "The Burden of Hospitalisations for Herpes Zoster Ophtalmicus in Spain (1997-2008)," World Journal of Vaccines, Vol. 2 No. 3, 2012, pp. 164-171. doi: 10.4236/wjv.2012.23022.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] S. Shaikh and C. N. Ta, “Evaluation and Management of Herpes Zoster Ophthalmicus,” American Family Physician, Vol. 66, No. 9, 2002, pp. 1723-1730.
[2] S. L. Thomas and A. J. Hall, “What Does Epidemiology Tell Us about Risk Factors for Herpes Zoster?” The Lancet Infectious Diseases, Vol. 4, No. 1, 2004, pp. 26-33. doi:10.1016/S1473-3099(03)00857-0
[3] R. W. Johnson, G. Wasner, P. Saddier and R. Baron, “Postherpetic Neuralgia: Epidemiology, Pathophysiology and Management,” Expert Review of Neurotherapeutics, Vol. 7, No. 11, 2007, pp. 1581-1595. doi:10.1586/14737175.7.11.1581
[4] K. Schmader, “Herpes Zoster in Older Adults,” Clinical Infectious Diseases, Vol. 32, No. 10, 2001, pp. 1481-1486. doi:10.1086/320169
[5] M. Vázquez and E. D. Shapiro, “Varicella Vaccine and Infection with Varicella-Zoster Virus,” The New England Journal of Medicine, Vol. 352, No. 5, 2005, pp. 439-440. doi:10.1056/NEJMp048320
[6] K. Galil, P. W. Choo, J. G. Donahue and R. Platt, “The Sequelae of Herpes Zoster,” Archives of Internal Medicine, Vol. 157, No. 11, 1997, pp. 1209-1213. doi:10.1001/archinte.1997.00440320105010
[7] R. E. Hope-Simpson, “Postherpetic Neuralgia,” The Journal of the Royal College of General Practitioners, Vol. 25, No. 157, 1975, pp. 571-575.
[8] W. J. Edmunds, M. Brisson and J. D. Rose, “The Epidemiology of Herpes Zoster and Potential Cost-Effectiveness of Vaccination in England and Wales,” Vaccine, Vol. 19, No. 23-24, 2001, pp. 3076-3090. doi:10.1016/S0264-410X(01)00044-5
[9] S. Helgason, G. Petursson, S. Gudmundsson and J. A. Sigurdsson, “Prevalence of Postherpetic Neuralgia after a First Episode of Herpes Zoster: Prospective Study with Long Term Follow up,” British Medical Journal, Vol. 321, No. 7264, 2000, pp. 794-796. doi:10.1136/bmj.321.7264.794
[10] A. L. Cunningham, J. Breuer, D. E. Dwyer, D. W. Gronow, R. D. Helme, J. C. Litt, M. J. Levin and C. R. Macintyre, “The Prevention and Management of Herpes Zoster,” Medical Journal of Australia, Vol. 188, No. 3, 2008, pp. 171-176
[11] D. Pavan-Langston, “Ophtalmic Zoster,” In A. M. Arvin and A. A. Gershon, Eds., Varicella-Zoster Virus—Virology and Clinical Management, Cambridge University Press, Cambridge, 2000, pp. 276-298. doi:10.1017/CBO9780511601194.016
[12] W. Opstelten and M. J. Zaal, “Managing Ophthalmic Herpes Zoster in Primary Care,” British Medical Journal, Vol. 331, No. 7509, 2005, pp. 147-151. doi:10.1136/bmj.331.7509.147
[13] W. P. Carter 3rd, C. A. Germann and M. R. Baumann, “Ophthalmic Diagnoses in the ED: Herpes Zoster Ophthalmicus,” The American Journal of Emergency Medicine, Vol. 26, No. 5, 2008, pp. 612-627. doi:10.1016/j.ajem.2007.08.013
[14] Schmader et al., “Study to Evaluate the Safety and Effectiveness of Zostavax? in Subjects 50-59 Years of Age (V211-022),” Clinical Infectious Diseases, Vol. 54, No. 7, 2012, pp. 922-928.
[15] A. Gil, R. Gil, A. Alvaro, M. S. Martín and A. González, “Burden of Herpes Zoster Requiring Hospitalization in Spain during a Seven-Year Period (1998–2004),” BMC Infectious Diseases, Vol. 9, No. 55, 2009. doi:10.1186/1471-2334-9-55
[16] Ministerio de Sanidad y Consumo, “Clasificación Internacional de Enfermedades 9 Revisión, Modificación clínica,” 1996, pp. 375-376.
[17] Instituto Nacional de la Salud, “Subdirección General de Coordinación Administrativa. Conjunto Mínimo Básico de Datos. Hospitales del INSALUD2001. Madrid 2002,” 2010.
[18] C. A. Rivero, “El Conjunto Mínimo Básico de Datos en el SNS: Inicios y Desarrollo Actual,” Revista Fuentes Estadísticas, Vol. 49, 2000, pp. 18-19.
[19] J. Schrey?gg, T. Stargardt, O. Tiemann and R. Busse, “Methods to Determine Reimbursement Rates for Diagnosis Related Groups (DRG): A Comparison of Nine European Countries,” Health Care Management Science, Vol. 9, No. 3, 2006, pp. 215-223. doi:10.1007/s10729-006-9040-1
[20] T. J. Liesegang, “Herpes Zoster Ophthalmicus Natural History, Risk Factors, Clinical Presentation, and Morbidity,” Ophthalmology, 115, Suppl. 2, 2008, pp. S3-S12. doi:10.1016/j.ophtha.2007.10.009
[21] P. LaRussa, “The Success of Varicella Vaccine,” Pediatric Annals, Vol. 31, No. 11, 2002, pp. 710-715.
[22] J. C. Bramley and I. G. Jones, “Epidemiology of Chickenpox in Scotland: 1981 to 1998,” Communicable Disease and Public Health, Vol. 3, 4, 2000, pp. 282-287.
[23] B. P. Yawn, P. Saddier, P. C. Wollan, J. L. St. Sauver, M. J. Kurland and L. Sy, “A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster before Zoster Vaccine Introduction,” Mayo Clinic Proceedings, Vol. 82, No. 11, 2007, pp. 1341-1349. doi:10.4065/82.11.1341
[24] C. M. García, J. Castilla, Y. Montes, J. Morán, A. Salaberri, F. Elía, Y. Floristán, I. Rodrigo, F. Irisarri, M. Arriazu, A. Zabala and A. Barricarte, “Incidencia de la Varicela y el Herpes Zoster Antes de la Introducción de la Vacunación Sistemática Infantil en Navarra, 2005-2006,” Anales del Sistema Sanitario de Navarra, Vol. 31, 2008, pp. 71-80.
[25] N. Pérez-Farinós, M. Ordobás, C. García-Frenández, L. García-Comas, S. Ca?ellas, I. Rodero, A. Gutiérrez-Rodríguez, J. García-Gutiérrez and R. Ramírez, “Varicella and Herpes Zoster in Madrid, Based on the Sentinel General Practitioner Network: 1997-2004,” BMC Infectious Diseases, Vol. 7, No. 59, 2007. doi:10.1186/1471-2334-7-59
[26] R. Insinga, R. F. Itzler, J. M. Pellissier, P. Saddier and A. A. Nikas, “The Incidence of Herpes Zoster in a United States Administrative Database,” Journal of General Internal Medicine, Vol. 20, No. 8, 2005, pp. 748-753. doi:10.1111/j.1525-1497.2005.0150.x
[27] A. Gautier, J. Breuer, D. Carrington, M. Martin and V. Rèmy, “Epidemiology and Cost of Herpes Zoster and Post-Herpetic Neuralgia in the United Kingdom,” Epidemiology & Infection, Vol. 137, No. 1, 2009, pp. 38-47. doi:10.1017/S0950268808000678
[28] Ch. Chidiac, J. Bruxelle, J. P. Daures, T. Hoang-Xuan, P. Morel, A. Leplège, A. El Hasnaoui and C. de Labareyre, “Characteristics of Patients with Herpes Zoster on Presentation to Practitioners in France,” Clinical Infectious Diseases, Vol. 33, No. 1, 2001, pp. 62-69. doi:10.1086/320884
[29] W. Opstelten, G. A. Van Essen, F. Schellevis, T. Verheij and K. Moons, “Gender as Independent Risk Factor for Herpes Zoster: A Population Based Study,” Annals of Epidemiology, Vol. 16, No. 9, 2006, pp. 692-695. doi:10.1016/j.annepidem.2005.12.002
[30] D. M. Fleming, K. W. Cross, W. A. Cobb and R. S. Chapmna, “Gender Difference in the Incidence of Shingles,” Epidemiology & Infection, Vol. 132, No. 1, 2004, pp. 1-5. doi:10.1017/S0950268803001523
[31] B. Law, C. Fitzsimon, L. Ford-Jones, N. MacDonald, P. Dèry and W. Vaudry, “Cost of Chickenpox in Canada: Part I. Cost of Uncomplicated Cases,” Pediatrics, Vol. 104, No. 1, 1999, pp. 1-6. doi:10.1542/peds.104.1.1
[32] E. Somekh, I. Dalal, T. Shohat, G. M. Ginsberg and O. Romano, “The Burden of Uncomplicated Cases of Chickenpox in Israel,” Journal of Infection, Vol. 45, No. 4, 2002, pp. 233-236. doi:10.1053/jinf.2002.1039
[33] M. Brisson, W. J. Edmunds, N. J. Gay, B. Law and G. De Serres, “Modelling the Impact of Immunization on the Epidemiology of Varicella Zoster Virus,” Epidemiology and Infection, Vol. 125, No. 3, 2002, pp. 651-669. doi:10.1017/S0950268800004714
[34] M. Salleras, et al., “Contacts with Children and Young People and Adult Risk of Suffering Herpes Zoster,” Vaccine, Vol. 29, No. 44, 2011, pp. 7602-7605. doi:10.1016/j.vaccine.2011.08.023
[35] J. M. Guillen, R. Gil-Prieto, A. Alvaro and A. Gil, “Burden of Adult Varicella Hospitalizations in Spain (2001-2007),” Human Vaccines and Immunotherapeutics, Vol. 6, No. 8, 2010, pp. 659-663. doi:10.4161/hv.6.8.12014
[36] A. S. Gurwood, J. Savochka and B. J. Sirgany, “Herpes Zoster Ophthalmicus,” Optometry, Vol. 73, No. 5, 2002, pp. 295-230.
[37] Zostavax SmPC, 2011.
[38] S. Peiro and J. Librero, “Evaluación de la Calidad a Partir del Conjunto Mínimo de Datos Básicos al Alta Hospitalaria,” Revista de Neurología, Vol. 29, 1999, pp. 651-661.
[39] Ministerio de Sanidad y Consumo, “Análisis y Desarrollo de los GDR en el Sistema Nacional de Salud,” 2010.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.